This therapeutic concept uses receptor-mediated transcytosis (RMT) shuttles — engineered protein scaffolds that bind to endogenous BBB receptors (primarily TfR1 and LRP1) with optimized affinity to induce transcytosis across brain capillary endothelial cells. These shuttles enable episodic delivery of large therapeutic payloads (particularly PROTACs, which are typically 700-1000 Da and otherwise cannot cross the blood-brain barrier) into the central nervous system via peripheral administration. The "shuttle" modality represents a platform technology: once validated, any CNS-targeting therapeutic can be fused to the shuttle for brain delivery[1][2].
PROTACs represent one of the most promising therapeutic modalities for neurodegenerative — they can selectively degrade pathological via the ubiquitin-proteasome system. However, the molecular weight of typical PROTACs (700-1000 Da) exceeds the BBB penetration threshold (~400-500 Da for optimal passive diffusion), and their efflux transporter substrate liability further limits brain exposure. Antibody-based approaches face similar barriers: even engineering BBB-crossing antibodies shows <1% brain uptake[3].
Receptor-mediated transcytosis exploits endogenous trafficking pathways:
TfR1 pathway: Transferrin receptor is highly expressed on brain endothelial cells (106-107 copies/cell). Anti-TfR1 antibodies bind the apical domain and undergo receptor-mediated endocytosis, followed by transcytosis to the basolateral membrane. Denali Therapeutics' TfR-enabled platform has demonstrated 10-30x brain exposure improvements in preclinical models[4].
LRP1 pathway: LRP1 is expressed on BBB endothelial cells and mediates uptake of ApoE-containing lipo. LRP1-mediated transcytosis has shown promise for delivering larger payloads including nanoparticles and adeno-associated viruses[5].
The key challenge is optimizing binding affinity: too strong = lysosomal trapping in endothelial cells; too weak = no brain entry. The "shuttle" approach uses intermediate-affinity binding to maximize transcytosis while minimizing intracellular retention.
PROTACs can degrade pathological tau protein and amyloid precursor protein (APP) derivatives. Current anti-amyloid antibodies show limited efficacy in later disease stages — intracellular clearance via PROTACs could provide additive benefit[6].
α-Synuclein PROTACs could target intracellular aggregates that drive neuronal death. The BBB shuttle enables peripheral delivery of these large molecules to reach the substantia nigra and cortex[7].
TDP-43 and SOD1 PROTACs could address the intracellular proteinopathies characteristic of ALS. The episodic delivery model is particularly relevant forALS, where sustained protein clearance may be needed.
MAPT mutation-associated tau, and C9orf72-associated dipeptide repeat , represent intracellular targets ideal for PROTAC-mediated degradation with BBB shuttle delivery.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | First-in-class platform combining RMT shuttles with PROTACs for episodic CNS delivery |
| Mechanistic Rationale | 9 | TfR1 and LRP1 transcytosis pathways well-validated; PROTAC degradation mechanism proven |
| Addresses Root Cause | 8 | Enables intracellular protein degrader delivery to neurons and glia |
| Delivery Feasibility | 7 | TfR1 shuttle platform already in clinical development (DNL310); PROTAC conjugation is the novel step |
| Safety Plausibility | 7 | Receptor-mediated delivery uses endogenous pathways; iron homeostasis requires monitoring |
| Combinability | 9 | Platform modality — can combine with any CNS therapeutic (PROTACs, ASOs, antibodies) |
| Biomarker Availability | 8 | Can use established CSF/plasma pTau, α-syn,NfL readouts; PK for shuttle exposure |
| De-risking Path | 8 | In vitro BBB models, rodent PK/PD, and non-human primate toxicology feasible |
| Multi-disease Potential | 9 | AD, PD, DLB, ALS, FTD, Huntington's — any proteinopathy with validated PROTAC target |
| Patient Impact | 8 | Could enable disease-modifying therapy for intracellular protein targets previously "undruggable" |
| Total | 72 |
| Organization | Approach | Status |
|---|---|---|
| Denali Therapeutics | TfR1-enabled enzyme replacement (DNL310) | Phase 1/2 for Hunter syndrome |
| Roche/Genentech | Anti-TfR1 brain delivery platform | Preclinical |
| AcureX Therapeutics | LRP1-mediated CNS delivery | Preclinical |
| Arvinas | PROTAC platform (multiple CNS targets) | Discovery stage |
| Kymera Therapeutics | STAT3 and IRAK4 PROTACs | Clinical for oncology |
Estimated Cost: $80-120M to Phase 2a
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | PROTAC delivery across BBB is highly novel; combining targeted protein degradation with brain delivery is cutting-edge |
| Mechanistic Rationale | 8 | Strong rationale: PROTACs require intracellular delivery; BBB transcytosis enables CNS activity |
| Root-Cause Coverage | 7 | Targets disease-causing proteins via degradation; depends on target selection |
| Delivery Feasibility | 4 | Major challenge: BBB is the primary barrier; transcytosis optimization is complex |
| Safety Plausibility | 6 | PROTACs can be designed for reversibility; off-target effects need monitoring |
| Combinability | 7 | Can combine with targeted therapy approaches; potential for precision medicine |
| Biomarker Availability | 6 | Target protein levels and downstream biomarkers can track engagement |
| De-risking Path | 4 | Novel modality requiring extensive CNS delivery and safety characterization |
| Multi-disease Potential | 7 | Applicable to any CNS disease with a targetable disease protein |
| Patient Impact | 7 | Could enable previously undruggable CNS targets; transformative if successful |
Total Score: 65/100
Pardridge WM. Targeted Delivery of Protein and Gene Medicines Through the Blood–Brain Barrier. Molecular Pharmaceutics. 2019. ↩︎
Lajoie JM, Shusta EV. Targeting Receptor-Mediated Transport for CNS Drug Delivery. Neurobiology of Disease. 2015. ↩︎
Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurobiology of Disease. 2013. ↩︎
Arguello A, et al. DNL310: A Novel TfR1-Targeting Enzyme Replacement Therapy for Hunter Syndrome. Molecular Genetics and Metabolism. 2020. ↩︎
Demeule M, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis. Journal of Pharmacology and Experimental Therapeutics. 2008. ↩︎
Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. 2022. ↩︎
Tardiff DF, et al. Discovery of targeted degraders for alpha-synuclein. Cell Chemical Biology. 2019. ↩︎